Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures

International Journal of Cardiology

Volumn 202, Issue , 2016, Pages 578-585

  Mar, Philip L ^a   Familtsev, Dmitry ^a   Ezekowitz, Michael D ^b   Lakkireddy, Dhanunjaya ^c   Gopinathannair, Rakesh ^a  

^a University of Louisville School of Medicine   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

Ablation; Bridging; NOAC; Periprocedural anticoagulation; Renal impairment

Indexed keywords

ACTIVATED CARBON; ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; ATRIAL FIBRILLATION; BLEEDING; CATHETER ABLATION; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; EPIDURAL CATHETER; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NEUROSURGERY; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SPINAL ANESTHESIA; THROMBOEMBOLISM; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING; DRUG EFFECTS; ECONOMICS; HEMORRHAGE; INTERNATIONAL NORMALIZED RATIO; METABOLISM; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; PROCEDURES; STROKE; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PERIOPERATIVE CARE; STROKE; THROMBOEMBOLISM; WITHHOLDING TREATMENT;

EID: 84960871152     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.09.035     Document Type: Review

References (107)

1. W.E. Wysokinski, and R.D. McBane III Periprocedural bridging management of anticoagulation Circulation 126 2012 486 490
2. J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, M. Mayr, A.K. Jaffer, M.H. Eckman, and et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e326S e350S
3. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
4. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 369 2013 2093 2104
5. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, and et al. Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
6. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
7. J.C. Lauffenburger, J.F. Farley, A.K. Gehi, D.H. Rhoney, M.A. Brookhart, and G. Fang Factors driving anticoagulant selection in patients with atrial fibrillation in the United States Am. J. Cardiol. 115 2015 1095 1101
8. C. Kasmeridis, S. Apostolakis, L. Ehlers, L.H. Rasmussen, G. Boriani, and G.Y. Lip Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants Pharmacoeconomics 31 2013 971 980
9. G. Breuer, D.R. Weiss, and J. Ringwald 'New' direct oral anticoagulants in the perioperative setting Curr. Opin. Anaesthesiol. 27 2014 409 419
10. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, and et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
11. O.Q. Yin, K. Tetsuya, and R. Miller Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation Eur. J. Clin. Pharmacol. 70 2014 1339 1351
12. Daiichi Sankyo Savaysa Prescribing Information 2015
13. B.A. Steinberg, E.D. Peterson, S. Kim, L. Thomas, B.J. Gersh, G.C. Fonarow, and et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation Circulation 131 2015 488 494
14. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
15. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, and et al. Oral apixaban for the treatment of acute venous thromboembolism N. Engl. J. Med. 369 2013 799 808
16. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, A.S. Gallus, and et al. Oral rivaroxaban for symptomatic venous thromboembolism N. Engl. J. Med. 363 2010 2499 2510
17. V.T.E.I. Hokusai, H.R. Buller, H. Decousus, M.A. Grosso, M. Mercuri, S. Middeldorp, and et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N. Engl. J. Med. 369 2013 1406 1415
18. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, and et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N. Engl. J. Med. 361 2009 2342 2352
19. C. Frost, S. Nepal, J. Wang, A. Schuster, W. Byon, R.A. Boyd, and et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 76 2013 776 786
20. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin. Pharmacol. Ther. 78 2005 412 421
21. K. Ogata, J. Mendell-Harary, M. Tachibana, H. Masumoto, T. Oguma, M. Kojima, and et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J. Clin. Pharmacol. 50 2010 743 753
22. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br. J. Clin. Pharmacol. 64 2007 292 303
23. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects Eur. J. Clin. Pharmacol. 61 2005 873 880
24. C. Frost, J. Wang, S. Nepal, A. Schuster, Y.C. Barrett, R. Mosqueda-Garcia, and et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Br. J. Clin. Pharmacol. 75 2013 476 487
25. Y.C. Barrett, Z. Wang, C. Frost, and A. Shenker Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Thromb. Haemost. 104 2010 1263 1271
26. J. Stangier, H. Stahle, K. Rathgen, and R. Fuhr Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Clin. Pharmacokinet. 47 2008 47 59
27. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, M. Feuring, and et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb. Haemost. 103 2010 1116 1127
28. Boehringer Ingelheim Pharmaceuticals. Pradaxa Prescribing Information 2015
29. J.D. Douketis, J.S. Healey, M. Brueckmann, J.W. Eikelboom, M.D. Ezekowitz, M. Fraessdorf, and et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial Thromb. Haemost. 113 2015 625 632
30. G.Y. Lip, L. Frison, J.L. Halperin, and D.A. Lane Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J. Am. Coll. Cardiol. 57 2011 173 180
31. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
32. Bristol-Myers Squibb Eliquis Prescribing Information 2014
33. Janssen Pharmaceuticals Xarelto Prescribing Information 2015
34. J.K. Schaefer, R.D. McBane, D.F. Black, L.N. Williams, K.G. Moder, and W.E. Wysokinski Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients Thromb. Haemost. 112 2014 947 950
35. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, H. Stahle, and et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J. Clin. Pharmacol. 45 2005 555 563
36. D. Kubitza, M. Becka, W. Mueck, A. Halabi, H. Maatouk, N. Klause, and et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor Br. J. Clin. Pharmacol. 70 2010 703 712
37. T.A. Leil, Y. Feng, L. Zhang, A. Paccaly, P. Mohan, and M. Pfister Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose Clin. Pharmacol. Ther. 88 2010 375 382
38. J. Stangier, K. Rathgen, H. Stahle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin. Pharmacokinet. 49 2010 259 268
39. I.F. Troconiz, C. Tillmann, K.H. Liesenfeld, H.G. Schafer, and J. Stangier Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery J. Clin. Pharmacol. 47 2007 371 382
40. W. Mueck, L.C. Borris, O.E. Dahl, S. Haas, M.V. Huisman, A.K. Kakkar, and et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb. Haemost. 100 2008 453 461
41. A.S. De Vriese, R. Caluwe, E. Bailleul, D. De Bacquer, D. Borrey, B. Van Vlem, and et al. Dose-finding study of rivaroxaban in hemodialysis patients Am. J. Kidney Dis. 66 1 2015 Jul 91 98
42. D.A. Parasrampuria, T. Marbury, N. Matsushima, S. Chen, P.K. Wickremasingha, L. He, and et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis Thromb. Haemost. 113 2015 719 727
43. P. Sardar, S. Chatterjee, E. Herzog, R. Nairooz, D. Mukherjee, and J.L. Halperin Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials Can. J. Cardiol. 30 2014 888 897
44. C.Y.Z. Frost, J. Wang, C. Li, C. Zeigler, A. Schuster, V. Ly, D. Zhang, and F. LaCreta Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment Clin. Pharmacol. Ther. 85 2009 S34 PI-84 (2013)
45. D. Kubitza, A. Roth, M. Becka, A. Alatrach, A. Halabi, H. Hinrichsen, and et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor Br. J. Clin. Pharmacol. 76 2013 89 98
46. J.R.G. Mendell, L. He, and S. Chen An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics Eur. Heart J. 33 2012 (Abstract 2024)
47. J. Stangier, H. Stahle, K. Rathgen, W. Roth, and K. Shakeri-Nejad Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment J. Clin. Pharmacol. 48 2008 1411 1419
48. W. Gogarten, E. Vandermeulen, H. Van Aken, S. Kozek, J.V. Llau, and C.M. Samama Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology Eur. J. Anaesthesiol. 27 2010 999 1015
49. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, S.P. Frostick, and et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J. Thromb. Haemost. 5 2007 2178 2185
50. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, S.P. Frostick, and et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
51. T. Fuji, C.J. Wang, S. Fujita, Y. Kawai, T. Kimura, and S. Tachibana Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan J. Arthroplasty 29 2014 2439 2446
52. T. Fuji, C.J. Wang, S. Fujita, Y. Kawai, M. Nakamura, T. Kimura, and et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial Thromb. Res. 134 2014 1198 1204
53. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, J. Muntz, and et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
54. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, and L.M. Ramirez Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N. Engl. J. Med. 363 2010 2487 2498
55. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
56. A.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, L.M. Kwong, and et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
57. Y. Falck-Ytter, C.W. Francis, N.A. Johanson, C. Curley, O.E. Dahl, S. Schulman, and et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e278S e325S
58. S. Rachidi, E.S. Aldin, C. Greenberg, B. Sachs, M. Streiff, and A.M. Zeidan The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery Expert. Rev. Hematol. 6 2013 677 695
59. J.L. Mega, E. Braunwald, S. Mohanavelu, P. Burton, R. Poulter, F. Misselwitz, and et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
60. J.H. Alexander, R.C. Becker, D.L. Bhatt, F. Cools, F. Crea, M. Dellborg, and et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
61. J. Oldgren, A. Budaj, C.B. Granger, Y. Khder, J. Roberts, A. Siegbahn, and et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur. Heart J. 32 2011 2781 2789
62. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, C. Bode, and et al. Rivaroxaban in patients with a recent acute coronary syndrome N. Engl. J. Med. 366 2012 9 19
63. A. Rubboli, D.P. Faxon, K.E. Juhani Airaksinen, A. Schlitt, F. Marin, D.L. Bhatt, and et al. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview Thromb. Haemost. 112 2014 1080 1087
64. W.J. Dewilde, T. Oirbans, F.W. Verheugt, J.C. Kelder, B.J. De Smet, J.P. Herrman, and et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
65. M. Lamberts, G.H. Gislason, J.B. Olesen, S.L. Kristensen, A.M. Schjerning Olsen, A. Mikkelsen, and et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention J. Am. Coll. Cardiol. 62 2013 981 989
66. A.L. Dans, S.J. Connolly, L. Wallentin, S. Yang, J. Nakamya, M. Brueckmann, and et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 2013 634 640
67. D.H. Birnie, J.S. Healey, G.A. Wells, A. Verma, A.S. Tang, A.D. Krahn, and et al. Pacemaker or defibrillator surgery without interruption of anticoagulation N. Engl. J. Med. 368 2013 2084 2093
68. O. Cano, A. Andres, R. Jimenez, J. Osca, P. Alonso, Y. Rodriguez, and et al. Systematic implantation of pacemaker/ICDs under active oral anticoagulation irrespective of patient's individual preoperative thromboembolic risk Pacing Clin. Electrophysiol. 38 6 2015 723 730
69. J.M.R. Pillarisetti, S. Reddy, M. Khalafi, A. Raghav, M. Sridhar, A. Kanmanthareddy, D. Atkins, M. Reddy, and D. Lakkireddy Peri-procedural use of novel anticoagulation agents during cardiac device implantation J. Am. Coll. Cardiol. 2014 2014 63
70. A. Tischenko, L.J. Gula, R. Yee, G.J. Klein, A.C. Skanes, and A.D. Krahn Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin Am. Heart J. 158 2009 252 256
71. X. Yang, Z. Wang, Y. Zhang, X. Yin, and Y. Hou The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: a meta-analysis Europace 17 7 2015 1076 1084
72. T. Nascimento, D.H. Birnie, J.S. Healey, A. Verma, J. Joza, M.L. Bernier, and et al. Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey Can. J. Cardiol. 30 2014 231 236
73. H.K. Li, F.C. Chen, R.F. Rea, S.J. Asirvatham, B.D. Powell, P.A. Friedman, and et al. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure Pacing Clin. Electrophysiol. 34 2011 868 874
74. R.T. Sant'anna, T.L. Leiria, T. Nascimento, J.R. Sant'anna, R.A. Kalil, G.G. Lima, and et al. Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: reappraisal after the BRUISE Study Pacing Clin. Electrophysiol. 38 2015 417 423
75. Heart Rhythm Society Taskforce 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation Heart Rhythm. 9 2012 632 696
76. P. Santangeli, L. Di Biase, R. Horton, J.D. Burkhardt, J. Sanchez, A. Al-Ahmad, and et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis Circ. Arrhythm. Electrophysiol. 5 2012 302 311
77. L. Di Biase, J.D. Burkhardt, P. Santangeli, P. Mohanty, J.E. Sanchez, R. Horton, and et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial Circulation 129 2014 2638 2644
78. T. Deneke, D.I. Shin, O. Balta, K. Bunz, F. Fassbender, A. Mugge, and et al. Postablation asymptomatic cerebral lesions: long-term follow-up using magnetic resonance imaging Heart Rhythm. 8 2011 1705 1711
79. L. Di Biase, F. Gaita, E. Toso, P. Santangeli, P. Mohanty, N. Rutledge, and et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study Heart Rhythm. 11 2014 791 798
80. M. Bassiouny, W. Saliba, J. Rickard, M. Shao, A. Sey, M. Diab, and et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation Circ. Arrhythm. Electrophysiol. 6 2013 460 466
81. J.S. Kim, F. She, K. Jongnarangsin, A. Chugh, R. Latchamsetty, H. Ghanbari, and et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation Heart Rhythm. 10 2013 483 489
82. D. Lakkireddy, Y.M. Reddy, L. Di Biase, S.R. Vanga, P. Santangeli, V. Swarup, and et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J. Am. Coll. Cardiol. 59 2012 1168 1174
83. P. Sardar, R. Nairooz, S. Chatterjee, J. Wetterslev, J. Ghosh, and W.S. Aronow Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation Am. J. Cardiol. 113 2014 1173 1177
84. D. Snipelisky, C. Kauffman, K. Prussak, G. Johns, K. Venkatachalam, and F. Kusumoto A comparison of bleeding complications post-ablation between warfarin and dabigatran J. Interv. Card. Electrophysiol. 35 2012 29 33
85. D. Lakkireddy, Y.M. Reddy, L. Di Biase, A. Vallakati, M.C. Mansour, P. Santangeli, and et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J. Am. Coll. Cardiol. 63 2014 982 988
86. R. Dillier, S. Ammar, G. Hessling, B. Kaess, H. Pavaci, A. Buiatti, and et al. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures Circ. Arrhythm. Electrophysiol. 7 2014 576 582
87. R. Cappato, F.E. Marchlinski, S.H. Hohnloser, G.V. Naccarelli, J. Xiang, D.J. Wilber, and et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation Eur. Heart J. 36 28 2015 Jul 21 1805 1811
88. L. Di Biase, D. Lakkireddy, C. Trivedi, T. Deneke, M. Martinek, S. Mohanty, and et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study Heart Rhythm. 9 4 2012 Apr 632 696.e21
89. T. Nagao, Y. Inden, M. Shimano, M. Fujita, S. Yanagisawa, H. Kato, and et al. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation Pacing Clin. Electrophysiol. 38 2015 155 163
90. H.L. Armbruster, J.P. Lindsley, M.P. Moranville, M. Habibi, I.M. Khurram, D.D. Spragg, and et al. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation Ann. Pharmacother. 49 2015 278 284
91. H. Calkins, K.H. Kuck, R. Cappato, J. Brugada, A.J. Camm, S.A. Chen, and et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design Heart Rhythm. 9 2012 632-96.e21
92. H. Calkins, E.P. Gerstenfeld, R. Schilling, A. Verma, and S. Willems RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy Am. J. Cardiol. 115 2015 154 155
93. E. Gehrie, and C. Tormey Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal Arch. Pathol. Lab. Med. 139 2015 687 692
94. A.M. Winkler, and C.A. Tormey Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients Am. J. Clin. Pathol. 140 2013 610 622
95. W.E. Dager, R.C. Gosselin, and A.J. Roberts Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity Crit. Care Med. 41 2013 e42 e46
96. L.E. Dumkow, J.R. Voss, M. Peters, and D.L. Jennings Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma Am. J. Health Syst. Pharm. 69 2012 1646 1650
97. T.E. Warkentin, P. Margetts, S.J. Connolly, A. Lamy, C. Ricci, and J.W. Eikelboom Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding Blood 119 2012 2172 2174
98. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
99. L.M. Harinstein, J.W. Morgan, and N. Russo Treatment of dabigatran-associated bleeding: case report and review of the literature J. Pharm. Pract. 26 2013 264 269
100. M.K. Korber, E. Langer, S. Ziemer, E. Perzborn, C. Gericke, and C. Heymann Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study Clin. Appl. Thromb. Hemost. 20 2014 735 740
101. G. Lu, F.R. DeGuzman, S.J. Hollenbach, M.J. Karbarz, K. Abe, G. Lee, and et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat. Med. 19 2013 446 451
102. E. Perzborn, A. Gruber, H. Tinel, U.M. Marzec, U. Buetehorn, A. Buchmueller, and et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates Thromb. Haemost. 110 2013 162 172
103. Crowther M.L. Gallia, Genmin Lu, Janet Leeds, Lee Barron, Pamela Conley, Janice Castillo, John Curnutte, and Stuart Connolly ANNEXA-A: a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors CS03 of the 2014 American Heart Association Conference. Chicago, Illinois 2014 (11/17/)
104. A.M. Gold, M. Crowther, G. Levy, G. Lu, J. Leeds, L. Barron, and et al. Annexatm-R: a Phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa (Prt064445), a universal antidote for factor Xa (Fxa) inhibitors J. Am. Coll. Cardiol. 65 2015 A23
105. N. Raghavan, C.E. Frost, Z. Yu, K. He, H. Zhang, W.G. Humphreys, and et al. Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab. Dispos. 37 2009 74 81
106. N.H. Holford Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship Clin. Pharmacokinet. 11 1986 483 504
107. AHFS Drug Information® 56th ed. 2015 Bethesda, MD American Society of Health-System Pharmacists